

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

19904-009

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/485571

INTERNATIONAL APPLICATION NO.
PCT/FR98/01757INTERNATIONAL FILING DATE
06 August 1998 (06.08.98)PRIORITY DATE CLAIMED
12 August 1997 (12.08.97)

TITLE OF INVENTION

LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, PREPARATION AND USE OF VECTORIZING
ACTIVE SUBSTANCES

APPLICANT(S) FOR DO/EO/US

CALAS, Bernard; GRASSY, Gerard; CHAVANIEU, Alain; KACZOREK, Michel

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

92bis Change of inventor's address

PCT/IB/304

PCT/IB/308

Post Card

Express Mailing Label No.: EL390999802US

Deposited: 11February 2000

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/485571		INTERNATIONAL APPLICATION NO. PCT/FR98/01757		ATTORNEY'S DOCKET NUMBER 19904-009	
--	--	--	--	--	--

21. The following fees are submitted:.				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO				\$970.00	
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO				\$840.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO				\$690.00	
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)				\$670.00	
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)				\$96.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$840.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30				\$130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	17 - 20 =	0	x \$18.00	\$0.00	
Independent claims	4 - 3 =	1	x \$78.00	\$78.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,048.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/>				\$0.00	
SUBTOTAL =				\$1,048.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 +				\$0.00	
TOTAL NATIONAL FEE =				\$1,048.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$1,048.00	
				Amount to be:	\$
				refunded	\$
				charged	\$

☒ A check in the amount of **\$1,048.00** to cover the above fees is enclosed.


☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **50-0311** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

ELRIFI, Ivor R.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111
United States of America



SIGNATURE

John T. Prince

NAME

43,019

REGISTRATION NUMBER

11 February 2000

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTORS:	Calas <i>et al.</i>
UNITED STATES NATIONAL PHASE OF PCT INTERNATIONAL APPLICATION NO:	PCT/FR98/01757
INTERNATIONAL FILING DATE:	August 6, 1997
FOR:	LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, PREPARATION AND USE FOR VECTORIZING ACTIVE SUBSTANCES

Box PCT

Assistant Commissioner for Patents
Washington, D.C. 20231

Boston, Massachusetts
February 11, 2000

PRELIMINARY AMENDMENT

Preliminary to examination, please amend the application as follows:

IN THE CLAIMS

Kindly amend claims 3, 5-8, 10, and 12-17 as follows:

3. (Amended) Linear peptide according to any one of claims 1 [to 2], characterised in that it meets one of the following formulas

BXXBXXXXBBBXXXXXXB (I)

BBXXBXXBXXXXBBXB (II)

in which

- the B groups, identical or different, represent an amino acid residue whose side chain carries a base group, and
- groups X, identical or different, represent an aliphatic or aromatic amino acid residue, or in that it is made up of a succession of at least 5, preferably at least 7, successive amino acids of either of formulas (I) or (II).

5. (Amended) Linear peptide according to one of claim[s] 3 [to 4], characterised in that the X groups are chosen from among glycine, alanine, valine, norleucine, isoleucine, leucine, cysteine, cysteine^{Acm}, penicillamine, methionine, serine, threonine, asparagine, glutamine, phenylalanine, histidine, tryptophan, tyrosine, proline, Abu, carboxylic amino-1-cyclohexane acid, Aib, carboxylic 2-aminotetraline, 4-bromophenylalanine, tert-leucine, 4-chlorophenylalanine, β -cyclohexylalanine, 3, 4-dichlorophenylalanine, 4-fluorophenylalanine, homoleucine, β -homoleucine, homophenylalanine, 4-methylphenylalanine, 1-naphthylalanine, 2-naphthylalanine, 4-nitrophenylalanine, 3-nitrotyrosine, norvaline, phenylglycine, 3-pyridylalanine, [2-thienyl] alanine.

6. (Amended) Linear peptide according to any one of claim[s] 1 [to 5], characterised in that it meets one of the following formulas

RXXRXUXURRRXUXXXR-NH₂ (V)

RRXUXRXUXRXXUXRRUR-NH₂ (VI)

in which

- U represents serine or threonine,
- R represents arginine, and
- the X groups, identical or different, represent an amino acid which may or may not be natural, including D-amino acids, either aliphatic or aromatic, such as glycine, alanine, valine, norleucine, isoleucine, leucine, cysteine, cysteine^{Acm}, penicillamine, methionine, serine, threonine, asparagine, glutamine, phenylalanine, histidine, tryptophan, tyrosine, proline, Abu, carboxylic amino-1-cyclohexane acid, Aib, carboxylic 2-aminotetraline, 4-bromophenylalanine, tert-leucine, 4-chlorophenylalanine, β -cyclohexylalanine, 3, 4-dichlorophenylalanine, 4-fluorophenylalanine, homoleucine, β -homoleucine, homophenylalanine, 4-methylphenylalanine, 1-naphthylalanine, 2-naphthylalanine, 4-nitrophenylalanine, 3-nitrotyrosine, norvaline, phenylglycine, 3-pyridylalanine, [2-thienyl] alanine.

7. (Amended) Linear peptide according to any one of claim[s] 1 [to 6], having the following sequences

RGGRLSYSRRRFSVSVGR,
RGVSVSFRRRSYSLRGGR,
EGGELSYSEEEFSVSVGE,
RGGRLAYRLLRFAIRVGR,
OGGOXXBOXXOBXXXOXG,
RAARLG YRXXRFGZRVGR,
YRRRFSVSVR,
RRLSYSRRRF,
RRLSYSRRRFSVSVR,
RGGRLSYSRRRFSTSTGR,

in which B represents Naphthylalanine, O represents Ornithine, X represents Norleucine and Z represents Norvaline.

8. (Amended) Linear peptide according to any one of claim[s] 1 [to 6], having the following sequences

KWSFRVSYRGISYRRSR,
RWSFRVSYRGISYRRSR,
RSRRYSIGRYSVRFSWK,
OBXBOXXBOGXOBXXOX,
KWA FRVAYRGIRYLLRL,
KYAWRVAHRGIRWLLRX

in which B represents Naphthylalanine, O represents Ornithine, X represents Norleucine and Z represents Norvaline.

10. (Amended) Use of a peptide according to any [one of claims 1 to 8] claim 1 to vector active substances in an organism.

12. (Amended) Compound of formula (IV) in which A is defined as in [any one of claims 1 to 8] claim 1.
13. (Amended) Compound according to [one of claims 11 or 12] claim 11, characterised in that the coupling between the linear peptide (A) and group (Z) or groups (Z) and (Y) is made by one or more covalent, hydrophobic or ionic bonds.
14. (Amended) Compound according to [any one of claims 11 to 13] claim 11, characterised in that at least one of the active substances (Z) is attached by a covalent bond either to the N-terminal or C-terminal ends or to the primary amino groups, carried by the side chains of the lysines, of linear peptide (A).
15. (Amended) Compound according to any [one of claims 11 to 14] claim 11, characterised in that at least one signal agent (Y), if present, is attached by a covalent bond to the N-terminal end of linear peptide (A).
16. (Amended) Pharmaceutical composition, characterised in that as active ingredient it comprises at least one compound of formula (TV) according to [any one of claims 11 to 15] claim 11.
17. (Amended) Diagnostic agent made up of at least one compound of formula (TV) according to any one of [claims 11 to 15] claim 11.

REMARKS


Applicant has amended claims 3, 5-8, 10, and 12-17 to remove dependency from multiple dependent claims. 37 C.F.R. § 1.75(c). No new matter is added.

INVENTORS: Calas *et al.*
UNITED STATES
NATIONAL PHASE OF PCT INTERNATIONAL
APPLICATION NO: PCT/FR98/01757

CONCLUSION

Applicant requests that the Examiner enter these amendments and issue these claims. If the Examiner has any further issues, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
John Prince, Reg. No. 43,019
Attorneys for Applicants

c/o MINIZ LEVIN COHN FERRIS GLOVSKY AND
POPEO PC
One Financial Center
Boston, Massachusetts 02111
Telephone: (617) 542-6000
Telefax: (617) 542-2241

TRADOCS:1294895.1(RR5B01!.DOC)
02/11/00 3:51 PM

09/485571

428 Rec'd PCT/PTO 11 FEB 2000

Abbaye Traductions

37, rue Amsterdam • 75008 PARIS • Tel: (1) 44.53.99.39 • Fax: (1) 49.95.94.78

VERIFICATION OF TRANSLATION

I, Mrs CRESPEL (name of translator)

Of Abbaye Traductions 37, rue Amsterdam 75008 PARIS (translator's address)

am the translator of Patent Application N° PCT/FR98/01757.

and I state that the following is a true translation to the best of my knowledge and belief.

Dated this 27th day of January 2000

Signature of translator

C.

LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES,
PREPARATION AND USE FOR VECTORING ACTIVE SUBSTANCES

The invention concerns linear peptides derived from antibiotic peptides and their use for vectoring active substances. More particularly, the subject of the invention is new compounds formed from a linear
5 derivative of an antibiotic peptide coupled to at least one active substance, and the preparation of these compounds and compositions containing them.

In addition to their immunity system responsible for specific defence mechanisms against infectious agents, vertebrates have numerous peptides with antimicrobial activity (Nicolas P. et al., 1995, Annual Rev. Microbiol. 49, 277-304). These peptides only exist in invertebrates having a short lifetime and a high renewal rate, in whom a memory immunity system, long in forming and developing appropriate response, is ill-adapted.

The anti-microbial peptides of vertebrates, irrespective of their origin, lower or higher vertebrates, myeloid or non-myeloid tissue, have a certain number of properties in common :

- 20 - high basicity due to the presence of
numerous arginines and lysines,
- the ability to form amphipathic
structures. By amphipathic structure is meant structures
in which the hydrophobic residues are separated in space
25 from hydrophilic residues,
- a very wide activity spectrum. They are
able to rapidly destroy bacteria (Gram⁺ and Gram⁻),
fungi, a few protozoa, membrane viruses and even some
cancer cell lines.

According to their structure, antibiotic peptides can be divided into three major families :

- amphipathic α -helical antibiotic peptides: cecropins and maganins (Maloy W.L. et al., 1995, BioPolymer 37, 105-122),

- β -stranded antibiotic peptides linked by disulphide bonds : defensins (Lehrer R.I. et al., 1991, Cell 64:229-230 ; Lehrer R.I. et al., 1993, Ann. Rev. Immunol. 11:105-128), protegrins (Kokryakov V.N. et al., 1993, FEBS 337:231-236), tachyplesins (Nakamura T. et al., 1988, J. Biol. Chem. 263:16709-16713 ; Miyata T. et al., 1989, J. Biochem. 106:663-668),

- antibiotic peptides having destructured chains with many angles due to the presence of multiple prolines : bactenecins and PR39 (Frank R.W. et al., 1991, Eur. J. Biochem. 202, 849-854).

Despite the diversity of their sequences, most antibiotic peptides act by direct lysis of the membrane of pathogenic cells. Their basicity promotes their interaction with negatively charged phospholipids, and being amphipathic they are subsequently able to incorporate themselves into the membrane in which they aggregate to form pores through which the cell loses its substance. It is generally accepted that their preferential selectivity for prokaryote cells is due to the special composition of their membranes which contain more anionic phospholipids than those of eukaryotes. Also, the plasma membranes of mammalian cells all contain cholesterol whose role is to modulate their fluidity, which could hinder the incorporation of antibiotic peptides. However, the specificity of the latter for

micro-organisms is low, meaning that they show strong cytotoxicity which limits their use.

The presence of antibiotic peptides in vertebrates, and more particularly in mammals, raises numerous queries. Immunologists assume that the compounds having non-specific anti-microbial activity found in invertebrates constitute an ancestral means of defence which later developed leading to much more complex memory systems. What is the advantage therefore, in mammals for example, of having preserved some peptides with antibiotic activity ? It is supposed that these small molecules that are always present in biological fluids, or sequestered in some lymphocyte structures, could form a first line of defence while awaiting the secretion of specific antibodies (Nicolas P. et al., 1995, Annual Rev. Microbiol. 49, 277-304). They could also, within the macrophages, take part in the destruction of plasma membranes of pathogenic organisms.

Regardless of their exact role, antibiotic peptides are of considerable interest owing to their wide spectrum of activity and the difficulty encountered by micro-organisms to set up inactivation strategies. On this account very numerous research studies have been conducted to endeavour to find new molecules and to obtain better performing analogues than the parent peptides. It is possible that in the future these antibiotic peptides are called upon to replace the antibiotics derived from bacteria or fungi. For example, PCT international patent applications published under numbers WO95/03325, WO96/37508 and WO97/02287 describe a new class of antibiotic peptides called "protegrins", isolated from porcine leukocytes or even prepared by

chemical synthesis or genetic engineering and having antibacterial, antiviral and antifungal activities.

At the present time, β -stranded antibiotic peptides linked by disulphide bonds (defensins, 5 protegrins, tachyplesins) are a particular subject of research on account of their powerful anti-microbial activity (bacteria, some viruses, fungi and parasites). Within this family, protegrins and tachyplesins are certainly the most promising molecules given the 10 simplicity of their structure and the relative ease with which they can be synthesised.

The name protegrins denotes a group of five peptides called PG-1, PG-2, PG-3, PG-4 and PG-5 whose sequences are given below, closely resembling and 15 isolated from porcine leukocytes (V.N. Kokryakov et al., FEBS lett. 327, 231-236) :

PG-1 : RGGRLCYCRRRFCVCVGR-NH₂

PG-2 : RGGRLCYCRRRFCICV..-NH₂

PG-3 : RGGGLCYCRRRFCVCVGR-NH₂

20 PG-4 : RGGRLCYCRGWICFCVGR-NH₂

PG-5 : RGGRLCYCRPRFCVCVGR-NH₂

Tachyplesins (Tamura H. et al., 1993, Chem. Pharm. Bul. Tokyo 41, 978-980) denoted T1, T2 and T3 and polyphemusins (Muta T., 1994, CIBA Found. Sym. 186, 160- 25 174) denoted P1 and P2 whose sequences are given below, are homologous peptides isolated from the hemolymph of two crabs *Tachyplesus tridentatus* for Tachyplesins T1, T2 and T3, and *Limulus polyphemus* for Polyphemusins P1 and P2.

30 P1 : RRWCFRVCYRGFCYRKCR-NH₂

P2 : RRWCFRVCYKGFCYRKCR-NH₂

T1 : KWCFRVCYRGICYRRCR-NH₂

T2 : RWCFRVCYRGICYRKCR-NH₂

T3 : KWCFRVCYRGICYKRCR-NH₂

5 Protegrins, tachyplesins and polyphemusins contain a high proportion of basic residues (lysines and arginines) and have four cysteines which form two parallel disulphide bonds. These three families of peptides also show homologies with some defensins in particular with the human defensin NP-1 (Kokryakov V.N. et al., 1993, Febs Let. 327, 231-236).

 Tachyplesins and protegrins have a closely resembling three-dimensional structure. It is an anti-parallel β strand stabilised by the two disulphide bonds. 15 These bonds play an important role in the antibacterial activity of protegrins and tachyplesins. Their removal, either by protecting the SH groups with acetamidomethyls, or by replacing the cysteines with alanines or glycines, leads to obtaining analogues virtually devoid of *in vivo* 20 activity (Lehrer R.I. et al., 1996, Eur. J. Biochem. 240:352-357).

 As previously indicated, protegrins and tachyplesins have substantial lysis activity on prokaryote cells. Research work conducted by the 25 Applicant on the cytotoxicity of these peptides on cultured mammalian cells, have shown that, prior to the death of the cells, there are non-negligible quantities of protegrins and tachyplesins in the cytoplasm of said cells. It was considered that the presence of peptides in 30 the cytoplasm could be the outcome of transport via pores, but these pores are only permeable to ions and small molecules and their diameter is too small to give

passageway to antibiotic peptides. It would seem that protegrins and tachyplesins, in addition to perforating the plasma membrane, are able to pass through it.

5 The cytotoxicity and antimicrobial activity of protegrins and tachyplesins are known to derive from their ability to aggregate inside the membrane to form multimeric channels (Mangoni M. et al., 1996, Febs Let. 383, 93-98). The Applicant therefore considered that this aggregation might be connected with the tertiary structure of these antibiotic peptides, which comprise several cysteine residues, and linear derivatives of protegrins and tachyplesins in which the cysteines are replaced by various natural amino acids have been prepared. These peptides were coupled, at their N-terminal end, to a fluorescent molecule or to biotin and the distribution of these markers inside the cell was observed under confocal microscopy.

10 In this way, it was found that these peptides are non-toxic and have no lytic activity but are, on the other hand, able to pass rapidly through the membranes of mammalian cells via a passive mechanism.

15 These linear derivatives of antibiotic peptides therefore constitute a new, non-toxic, system for vectoring active substances.

20 By vectoring system is meant, according to the invention, a process capable of conveying said active substance to a target, such as for example :

25 - to cause an active substance to pass through the cell membrane and to allow the distribution of said substance in the cytoplasm and/or in the nuclear compartment.

- to bring an active substance to a particular organ, for example to cause this active substance to pass through the blood-brain barrier,

- to force this active substance to interact specifically with a given cell type, erythrocytes for example.

The subject of the present invention is therefore peptides derived from antibiotic peptides or analogues thereof, characterised in that they are devoid of a disulphide bond.

By analogue of antibiotic peptides is meant a peptide whose amino acid sequence has been modified without causing any modification in the antibiotic properties of said peptide.

The absence of a disulphide bond in the peptides of the invention, may be obtained by any means known to those skilled in the art, for example by :

- removing, or replacing with other amino acids, the cysteine residues of the antibiotic peptide sequence,

- blocking the -SH groups of the cysteine residues such that they do not form a disulphide bond,

provided, evidently, that the peptide obtained has vectoring properties that are not toxic for the previously described cells.



These modifications may be conducted during the preparation of the peptides of the invention, more particularly by chemical synthesis or the expression of a gene coding for said peptide, or directly on an antibiotic peptide through the action of chemical agents

enabling the opening and blocking of the -SH groups of the cysteine residues.


The above modifications advantageously concern all the cysteine residues of the antibiotic peptide, but
 5 should the presence of a single cysteine residue not allow the formation of a disulphide bond, the peptides of the invention may contain a single cysteine. Natural antibiotic peptides generally have 4 or 6 cysteine residues able to form two or three disulphide bonds,
 10 therefore in the peptides of the invention only one of these cysteines can be maintained and the three or five others are modified or blocked.

The antibiotic peptides from which the peptides of the invention are derived may be defensins,
 15 protegrins, tachyplesins or their analogues whose antibiotic properties are imparted to them by their tertiary structure resulting from the presence of disulphide bonds.

Linear peptides of the invention meet one of the
 20 following formulas :



which may also be represented by the following single formula (III) :



in which :

- the B groups, identical or different, represent an amino acid residue whose side chain carries a base group, and
- 30 - the X groups, identical or different, represent an aliphatic or aromatic amino acid residue,

or are made up of a sequence of at least 5, preferably at least 7, successive amino acids of either of formulas (I) or (II), if this sequence has vectoring properties that are non-toxic for the previously
 5 described cells.

B and X may or may not be natural amino acids, including D-amino acids.


As an example the following denotations of B and X may be cited :

10 - B is chosen from among arginine, lysine, diaminoacetic acid, diaminobutyric acid, diaminopropionic acid, ornithine.

 - X is chosen from among glycine, alanine, valine, norleucine, isoleucine, leucine, cysteine,
 15 cysteine^{Acm}, penicillamine, methionine, serine, threonine, asparagine, glutamine, phenylalanine, histidine, tryptophan, tyrosine, proline, Abu, carboxylic amino-1-cyclohexane acid, Aib, carboxylic 2-aminotetraline, 4-bromophenylalanine, tert-Leucine, 4-chlorophenylalanine,
 20 β -cyclohexylalanine, 3,4-dichlorophenylalanine, 4-fluorophenylalanine, homoleucine, β -homoleucine, homophenylalanine, 4-methylphenylalanine, 1-naphthylalanine, 2-naphthylalanine, 4-nitrophenylalanine, 3-nitrotyrosine, norvaline, phenylglycine, 3-
 25 pyridylalanine, [2-thienyl]alanine.

The invention also concerns peptide derivatives having the formula (I) or (II) such as said peptides in retro form, or moieties of peptides having the formula (I) or (II) made up of five, preferably seven, successive
 30 amino acids of either formula (I) or (II).

Among the peptides of the invention, special mention can be made of those meeting the following formulas :



in which :

- U represents serine or threonine
 - R represents arginine, and
 - the X groups, identical or different,
- 10 represent an amino acid which may or may not be natural (including D-amino acids), either aliphatic or aromatic, such as glycine, alanine, valine, norleucine, isoleucine, leucine, cysteine, cysteine^{AcM}, penicillamine, methionine, serine, threonine, asparagine, glutamine, phenylalanine,
- 15 histidine, tryptophan, tyrosine, proline, Abu, carboxylic amino-1-cyclohexane acid, Aib, carboxylic 2-aminotetraline, 4-bromophenylalanine, tert-Leucine, 4-chlorophenylalanine, β -cyclohexylalanine, 3,4-dichlorophenylalanine, 4-fluorophenylalanine,
- 20 homoleucine, β -homoleucine, homophenylalanine, 4-methylphenylalanine, 1-naphthylalanine, 2-naphthylalanine, 4-nitrophenylalanine, 3-nitrotyrosine, norvaline, phenylglycine, 3-pyridylalanine, [2-thienyl]alanine.

- 25 Among the peptides of formulas (I) and (II) or their derivatives, the invention specifically considers those derived from protegrins and tachyplesins referred to in tables I and II below.

Table I : Protegrin derivatives

Code	Sequence	Modification
SM1738	RGGRLSYSRRRFSVSVGR	Head of series
SM1736	rggrlsysrrrfsvsvgr	Aa of D form of SM1738
SM1727	RGVSVSFRRRSYSLRGGR	Retro form of SM1738
SM1739	EGGELSYSEEEFSVSVGE	Reversed charge (R → E)
SM2187	RGGRLAYRLLRFAIRVGR	Increased amphipathicity
SM2188	OGGOXXBOXXOBXXXOXG	Increased hydrophobicity
SM2189	RAARLGYRXXRFGZRVGR	Increased amphipathicity
SM2194	YRRRFSVSVR	C-terminal end of SM2193
SM2195	RRLSYSRRRF	N-terminal end of SM2193
SM2193	RRLSYSRRRFSVSVR	Reduced flexibility (G deletion)
SM2196	RGGRLSYSRRRFESTSTGR	Inhibition dimerisation

Table II : Tachyplesin derivatives

Code	Sequence	Modification
SM1726	KWSFRVSYRGISYRRSR	Head of series
SM2307	RWSFRVSYRGISYRRSR	K → R mutation
SM2392	rwsfrvsyrgisyrrsr	Aa of D form (of SM2307)
SM2309	kwsfrvsyrgisyrrsr	Aa of D form (of SM1726)
SM2310	RSRRYSIGRYSVRFSWK	Retro form
SM2190	OBXBOXXBOGXOBXXOX	Increased hydrophobicity
SM2191	KWAFRVAYRGIRYLLRL	Increased amphipathicity
SM2192	KYAWRVAHRGIRWLLRX	Increased amphipathicity


In the sequences of tables I and II above, B represents Naphthylalanine, O represents Ornithine, X represents Norleucine and Z represents Norvaline.

The invention also concerns the use of the above peptides for vectoring one or more active substances both for therapeutic and for diagnostic applications. As active substance, the invention gives particular

consideration to proteins or moieties of proteins, such as polypeptides or peptides, antibodies or parts of antibodies, nucleic acids and oligonucleotides or ribozymes, or even, obviously, active chemical molecules
 5 for the treatment or prevention of human or animal pathologies, such as for example, but not restricted to, anti-tumorals, antivirals, anti-inflammatories, agents preventing the degradation of organs and/or tissues, etc...

10 In the field of diagnostics, the active substance may be a radioactive marker, a stain marker, or any other means or substance able to reveal a metabolism or a pathology.

A further purpose of the invention is therefore
 15 compounds of formula (IV) as follows and compositions containing them :



in which :

- A represents a linear peptide derived from an
 20 antibiotic peptide in accordance with the invention,

- Z represents an active substance, such as defined above,

- Y represents a signal agent,

- n is 0 or more, advantageously 0 or 1,

25 - m is 1 or more, preferably up to 10, advantageously up to 5.

Therefore, the above formula (IV) compounds are formed from a peptide of the invention coupled with one or more active substances, identical or different,
 30 represented by the (Z) group in formula (IV), and optionally one or more signal agents, represented by the

(Y) group in formula (IV), having an addressing role for the compound of formula (IV) towards a cell type, a site or cell compartment or a given tissue. More particularly, the signal agent (Y) is an oligopeptide or a protein, such as a signal peptide, a nuclear localising signal, an antibody moiety, or a chemical molecule ligand or anti-ligand of a receptor.

In a special embodiment of the compounds of formula (IV), group (Y) is fixed to group (Z).

This coupling, symbolised by the horizontal lines in formula (IV), may be conducted by any acceptable linking means, taking into consideration the chemical nature, the size and number of groups (Z) and (Y) in the compounds of formula (IV), such as covalent, hydrophobic or ionic bonds, which may or may not be cleaved in physiological media. Coupling may be conducted at any site of peptide (A), at which functional groups such as -OH, -SH, -COOH, -NH₂ are naturally present or have been inserted.

The invention gives consideration to the fixation of several (Z) groups to one and the same site of peptide (A) either directly, if this site comprises several functional groups as is the case for a C- or N-terminal lysine, or indirectly via an intermediate group carrying several reaction groups enabling the fixation of several (Z) groups.

The preferred coupling positions for the active substance are at the N-terminal and C-terminal ends or at the primary amino groups carried by the side chains of the lysines of peptide (A). If the C-terminal end of peptide (A) is used to attach active substance (Z), the N-terminal end is available for optional coupling to a signal agent (Y) enabling the compound of the invention

to be addressed either towards the nucleus, or towards a given tissue type.

For example, if the C-terminal end of a linear peptide of the invention is used to couple an active
5 substance made up of a fluorescent marker, or biotin, or a medicinal molecule such as doxorubicin, the covalent peptide-drug complex distributes itself after administration within the cytoplasm of the target cell. It is possible to bring this complex into the nuclear
10 compartment by using the N-terminal end of the peptide to couple a short basic sequence, for example of around 7 amino acids, corresponding to a nuclear localising signal. Under these conditions, the biotin or doxorubicin are found in the cell nucleus.

15 In the same way, it is possible to vector a drug towards a given cell type, by using the N-terminal end of the linear peptide of the invention coupled at its C-terminal end to a medicinal agent, to add a peptide sequence able to specifically recognise a determinant
20 present on the surface of cell type. Synthetic pentadecapeptide α M2 for example (Swolapenko G.B. et al., 1995, The Lancet 346, 1662-65) a moiety of a monoclonal antibody, directed against an antigen expressed by breast cancer cells (Tumour Associated Antigen Polymorphic
25 Epithelial Mucin) maintains good affinity for these cells. It is therefore possible, by associating α M2 with a linear peptide-medicinal agent complex, to bring this group preferably towards the cells which express the antigen characteristic related to breast cancer.

30 The compounds of formula (IV) may be prepared by chemical synthesis or by using molecular biology techniques.

For chemical syntheses, commercially available equipment can be used allowing the incorporation of non-natural amino acids, such as D enantiomers and residues with side chains of different hydrophobicity and size to those of their natural homologues. At the time of synthesis it is evidently possible to conduct a wide range of modifications, for example to insert a lipid (prenyl or myristyl) on the N-terminal so as to be able to anchor the peptide of the invention and hence the formula (IV) compound to a lipid membrane such as that of a liposome made up of positively charged lipids. It is also possible to replace one or more peptide bonds (-CO-NH-) by equivalent structures such as -CO-N(CH₃)-, -CH₂-CH₂-, -CO-CH₂-, or to interpose groups such as -CH₂-, -NH-, -O-.

It is also possible to obtain formula (IV) compounds, or part thereof having a protein nature, from an encoding nucleic acid sequence. A further purpose of the invention is a nucleic acid molecule comprising or made up of a nucleic sequence coding for a linear peptide derived from an antibiotic peptide. More particularly, the invention concerns a nucleic acid molecule comprising at least one sequence coding for a formula (IV) compound or part thereof having a protein nature. These nucleic acid sequences may be DNAs or RNAs and be associated with control sequences and/or inserted in vectors. The vector used is chosen in relation to the host to which it will be transferred ; it may be any vector such as a plasmid. These nucleic acids and vectors are useful for producing the linear peptides and formula (IV) compounds, or part of the latter having a protein nature, in a host cell. The preparation of these vectors and the production or expression in a host of linear peptides or formula (IV) compounds may be conducted using molecular biology and

genetic engineering techniques well known to those skilled in the art.

By way of example, said method for producing a peptide of the invention consists of :

- 5 - transferring a nucleic acid molecule or a vector containing said molecule into a host cell,
- culturing said host cell under conditions enabling the production of the peptide,
- isolating, by any appropriate means, the
10 peptides of the invention.

The host cell used in this type of method may be chosen from among prokaryotes or eukaryotes, in particular from among bacteria, yeasts, mammalian, plant or insect cells. The invention therefore also concerns
15 transformed cells expressing the linear peptides or formula (IV) compounds or part of the latter having a protein nature.

The invention also relates to :

- 20 - pharmaceutical compositions comprising as active ingredient at least one formula (IV) compound optionally associated with an acceptable vehicle or carrier,
- diagnostic agents containing at least one formula (IV) compound.

25 Other characteristics and advantages of the invention will become apparent in the following description concerning the preparation of formula (IV) compounds and the research work which led to revealing the vectoring properties of the linear peptides of the
30 invention derived from antibiotic peptides.

Example 1 : Fixing biotin and doxorubicin onto linear analogues of antibiotic peptides.

1) Preparation of linear peptides

The three peptides with the sequences given below
5 were synthesised :

RGGRLXYXRRRFXVXVGR-NH₂

RRWXFRVXYRGFXRKR-NH₂

KWXFRVXYRGIXYRRXR-NH₂

in which X represents the serine, threonine or
10 alanine residues.

These peptides are respectively derived from the sequences of Protegrin PG-1 having the formula :

RGGRLCYCRRRFCVCVGR-NH₂

of Tachyplesin 1 having the formula :

15 KWCFRVXYRGICYRRCR-NH₂

of Polyphemusin having the formula :

KWXFRVXYRGIXYRRXR-NH₂

These three peptides may be prepared indifferently either from BOC chemistry or from FMOC
20 chemistry using conventional synthesis methods in solid or homogeneous phase.

2) Fixing biotin onto linear peptides

The peptide is synthesised in solid phase and, after incorporation of the N-terminal arginine, 5-
25 aminopentanoic acid is added. The FMOC or BOC N-terminal is removed, and on the peptide still adhering to the resin, the N-hydroxy succimido biotin ester is caused to react in dimethylformamide. After 15 hours' reaction at room temperature, the biotinylated peptide is cut from

the carrier through the action of trifluoroacetic acid or hydrofluoric acid following well-established protocols in peptide chemistry. The peptide is then purified by high pressure liquid chromatography.

5 3) Fixing doxorubicin onto a linear peptide

To fix doxorubicin, solid phase synthesis is made of the peptide having the formula :



After cleaving from the purification substrate,
10 the peptide is treated with glutaric anhydride in the presence of triethylamine. The peptide is then purified and the -COOH group carried by the glutaryl at the N-terminal is activated by the diisopropylcarbodiimide and 1-hydroxybenzotriazole mixture. After two hours' reaction
15 at room temperature, the doxorubicin is added and the mixture is stirred for 12 hours at 0°C. The peptide-doxorubicin unit is then purified by high pressure liquid chromatography.

20 Example 2 : Ability of the linear peptides of the invention to pass through cell membranes.

1) Cell models

The ability of the peptides to pass through the membranes was tested on various cell types (MCF7, MCF7R, HL60, HL60R, HeLa).

25 The cells are cultured on RPMI 1640 (Gibco) to which is added 10 % (v/v) fetal calf serum, 2mM glutamine and 2mM pencillin/streptomycin at 37°C. 30 000 cells are seeded in Lab Tek chambers and cultured for 1 day.

30 2) Treatment with linear peptides-biotin prepared according to example 1 (2)

The cells are incubated in Opti-Mem (Gibco) for one hour before being treated for variable time periods with biotin-labelled peptides.

The latter are obtained in accordance with
5 example 1 (2) by treating 1 equivalent of linear peptide
with 2 equivalents of N-hydroxysuccinimide biotin ester,
then purified by high pressure liquid chromatography.

The cells are then fixed with a 3.7 % solution of paraformaldehyde for 5 minutes at 25°C, then rinsed three times with PBS. They are then permeabilised with 0.1 % Triton (1 min. room temperature). After three rinsings in PBS the cells are incubated 10 min with 200 µl TexRed antibodies diluted to 300th and rinsed three times in PBS. The slides are finally mounted with a Mowiol-Dabco solution and observed under an Axiophot photomicroscope.

3) Treatment with linear peptides-doxorubicin
prepared in accordance with example 1 (3)

The cells are incubated for 15 minutes, then rinsed with PBS and the doxorubicin present in the cell is determined by chromatography.

4) Results

a) Among the peptides studied, those which pass the most easily through the membranes are those with the following formulas :

25 $\text{RXXRXUXURRRXUXXXR-NH}_2$ (V)

$\text{RRXUXRXUXRXXUXRRUR-NH}_2$ (VI)

in which

- U represents serine or threonine,
- R represents arginine, and

- the X groups, identical or different, represent an amino acid which may or may not be natural (including D-amino acids), either aliphatic or aromatic, such as glycine, alanine, valine, norleucine, isoleucine, leucine, cysteine, cysteine^{AcM}, penicillamine, methionine, serine, threonine, asparagine, glutamine, phenylalanine, histidine, tryptophan, tyrosine, proline, Abu, carboxylic amino-1-cyclohexane acid, Aib, carboxylic 2-aminotetraline, 4-bromophenylalanine, tert-Leucine, 4-chlorophenylalanine, β -cyclohexylalanine, 3,4-dichlorophenylalanine, 4-fluorophenylalanine, homoleucine, β -homoleucine, homophenylalanine, 4-methylphenylalanine, 1-naphthylalanine, 2-naphthylalanine, 4-nitrophenylalanine, 3-nitrotyrosine, norvaline, phenylglycine, 3-pyridylalanine, [2-thienyl]alanine.

b) The results of the experiments conducted with doxorubicin show a significant increase in the plasma and nuclear concentration of doxorubicin when the latter is coupled with the linear peptide of the invention compared with the use of doxorubicin alone.

c) The experiments with biotin were conducted more especially on MCF7 cells treated at different times with a complex of biotin and a peptide of the invention having the formula :



This work was photographed (not shown) :

- Control in which the cell was treated with biotin alone,
- Treatment of the cell for 2 minutes with a complex : biotin-linear peptide of the invention,

- Treatment of the cell for 30 minutes with a complex: biotin-linear peptide of the invention.

It can be seen in these photographs that biotin alone does not enter the cell and accumulates weakly around the cell. Conversely, with the complex of the invention, it can be seen that the biotin is rapidly led by the linear peptide of the invention inside the cell in which it is present in the cytoplasm and cell nucleus.

Example 3 : Internalisation ability of the linear peptides of the invention

Linear peptides of the invention derived from Protegrins and Tachyplesins were tested on different cell lines for the purposes of assessing their respective internalisation.

1) Experimental conditions

The cells were seeded at approximately 10^4 cells per dish, 24 h before the addition of biotinylated peptides. On the day of the experiment confluence was 60-80%. The biotinylated peptides are incubated with the cells at a concentration of $10 \mu\text{M}$ for 15 minutes at 37°C in an atmosphere of 95% humidity and 5% CO_2 in an OptiMem medium. The cells are washed three times with PBS at room temperature and are then fixed with formalin (3.7% formaldehyde in PBS, 10 min at room temperature). They are then washed in PBS and permeabilised for 15 min with PBS-TritonX-100. Development is made with streptavidin-Texas-Red for 15 min away from light and the cells are then slide mounted. They are observed under a fluorescence microscope and compared with a positive control (Ap43-58), well described in the literature, and with a negative control.

The cell nuclei were Hoechst stained.

2) Cell lines

All the lines tested are of human origin and were commercially obtained from ATCC.

- Non-tumoral lines : MRC5 (lung fibroblast),
5 HuVeC (endothelial, umbilical cord)

- Tumoral lines : HT29 (colon carcinoma), HepG2 (hepatoblastoma), A172 (glioblastoma), HMCB (melanoma).

The cells are cultured at 37°C in an atmosphere of 95% humidity and 5% CO₂. The culture medium is the one
10 recommended by ATCC.

3) Tested peptides

The two series of tested peptides are those given in tables I and II.

4) Results

15 The internalisation results are shown in tables III and IV below. The peptides penetrate the cells with different degrees of internalisation. Some (such as SM1739 and SM2190) are not internalised whereas others (such as SM2307, SM2187 etc...) penetrate with good
20 efficacy. We also observed that some peptides enter into a given cell type more than in others. SM2196 for example has better internalisation in tumoral cells (HepG2, A172 and HT29) than in non-tumoral cells (MRC5 and HuVeC). Conversely, the SM1738 peptide has greater penetration
25 in non-tumoral lines than in tumoral lines. These results suggest the existence of cell tropism.

Generally it would appear that the retro form of the heads of series does not significantly modify internalisation. Increased hydrophobicity has a negative
30 effect for both families of tested peptides. It is therefore advisable to avoid increasing hydrophobia. On

the other hand, an increase in amphipathicity seems to have a positive effect at least for the Protegrin family.

Table III : Protegrin derivatives

	HepG2	A172	HMCB	HuVeC	MRC5	HT29	Internalisation
SM1738	+	+	+	+++	+++	+	Reference
SM1727	0	++	++	+++	+	+	No significant effect
SM1736	++	+	+++	++++	++++	+	No significant effect
SM1739	0	+	+	0	0	0	Negative effect
SM2187	+++	+++	++++	+++	++++	+++	Positive effect
SM2189	+++	++	+++	++	++++	++	Positive effect
SM2188	0	0	0	++	0	0	Negative effect
SM2193	++	++	+++	++	0	0	Negative effect
SM2194	0	+	+++	+	+	0	Negative effect
SM2195	++++	0	+++	+	+	++++	Contradictory
SM2196	++++	++++	++	+	+	++++	Tropism

5 Fluorescence microscopy photographs of internalisation are shown in figures 1 and 2. In the A172 and HT29 lines, the SM1738 peptide, shown as an example, appears to be mainly localised in the cytoplasm and in a perinuclear zone. For the HuVec line, the peptide is
10 mainly localised in the cytoplasm. The left column corresponds to nucleus staining with Hoechst.

Table IV : Tachyplesin derivatives

	HepG2	A172	HMCB	HuVeC	MRC5	HT29	Internalisation
SM1726	+++	+	++++	+++	+++	+++	Reference
SM2310	ND	++	++++	+++	++	+++	No effect
SM2309	ND	++++	++	++	++++	++++	ND
SM2191	++	++	++	ND	+++	+++	No effect
SM2192	+	+++	++++	+++	++++	++	No effect

SM2190	0	0	0	0	0	0	Negative effect
SM2307	ND	+++++	+++++	++++	++++	+++++	Positive effect
SM2392	ND	+++	++++	++	+++	++++	No effect

ND = not determined

The internalisation photographs are shown in appended figures 3 and 4. For the 3 cell lines shown (A172, HT29, HuVeC) the biotinylated peptide is localised in the cytoplasm in diffuse manner and also distinctly labels the nucleolus. The left column corresponds to nucleus staining with Hoechst.

Example 4 : Internalisation of vectored doxorubicin

The cells are seeded to approximately 10^4 cells per dish 24 h before the addition of the products. On the day of the experiment confluence is 60-80%. The free doxorubicin or the doxorubicin coupled to the SM1738 vector are incubated with the MCF7 cells at a concentration of 10 μ M for 60 minutes at 37°C in an atmosphere of 95% humidity and 5% CO₂ in the culture medium. The subcell localisation of doxorubicin, naturally fluorescent, was determined by confocal microscopy. The results are given in appended figure 5. The localisation is partly cytoplasmic and partly nuclear. The nucleus in this case is labelled in diffuse manner.

In the peptide sequences listed below, the amino acids are represented by their one-letter code, but they may also be represented by their three-letter code according to the following nomenclature :

A Ala alanine

5	C	Cys	cysteine
	D	Asp	aspartic acid
	E	Glu	glutamic acid
	F	Phe	phenylalanine
	G	Gly	glycine
10	H	His	histidine
	I	Ile	isoleucine
	K	Lys	lysine
	L	Leu	leucine
	M	Met	methionine
15	N	Asn	asparagine
	P	Pro	proline
	Q	Gln	glutamine
	R	Arg	arginine
	S	Ser	serine
	T	Thr	threonine
	V	Val	valine
	W	Trp	tryptophan
	Y	Tyr	tyrosine

CLAIMS

1. Peptide derived from an antibiotic peptide or an analogue thereof, characterised in that it is devoid of a disulphide bond.

5

2. Peptide derived from an antibiotic peptide or an analogue thereof, characterised in that all the cysteine residues, optionally except one, are removed, replaced by another amino acid residue or blocked at their SH group level.

10

3. Linear peptide according to any one of claims 1 to 2, characterised in that it meets one of the following formulas :

15

BXXBXXXXBBBXXXXXXB (I)

BBXXBXXXXBXXXXBBXB (II)

in which :

20

- the B groups, identical or different, represent an amino acid residue whose side chain carries a base group, and

- groups X, identical or different, represent an aliphatic or aromatic amino acid residue,

25

or in that it is made up of a succession of at least 5, preferably at least 7, successive amino acids of either of formulas (I) or (II).

30

4. Linear peptide according to claim 3, characterised in that the B groups are chosen from among arginine, lysine, diaminoacetic acid, diaminobutyric acid, diaminopropionic acid, ornithine.

5. Linear peptide according to one of claims 3 to 4, characterised in that the X groups are chosen from among glycine, alanine, valine, norleucine, isoleucine, leucine, cysteine, cysteine^{Acm}, penicillamine, methionine, 5 serine, threonine, asparagine, glutamine, phenylalanine, histidine, tryptophan, tyrosine, proline, Abu, carboxylic amino-1-cyclohexane acid, Aib, carboxylic 2-aminotetraline, 4-bromophenylalanine, tert-Leucine, 4-chlorophenylalanine, β -cyclohexylalanine, 3,4-10 dichlorophenylalanine, 4-fluorophenylalanine, homoleucine, β -homoleucine, homophenylalanine, 4-methylphenylalanine, 1-naphthylalanine, 2-naphthylalanine, 4-nitrophenylalanine, 3-nitrotyrosine, norvaline, phenylglycine, 3-pyridylalanine, [2-15 thienyl]alanine.

6. Linear peptide according to any one of claims 1 to 5, characterised in that it meets one of the following formulas :

20 $RXXRXUXURRRXUXUXXR-NH_2$ (V)
 $RRXUXRXUXRXXUXRRUR-NH_2$ (VI)

in which :

- U represents serine or threonine,
- R represents arginine, and
- 25 - the X groups, identical or different, represent an amino acid which may or may not be natural, including D-amino acids, either aliphatic or aromatic, such as glycine, alanine, valine, norleucine, isoleucine, leucine, cysteine, cysteine^{Acm}, penicillamine, methionine, 30 serine, threonine, asparagine, glutamine, phenylalanine, histidine, tryptophan, tyrosine, proline, Abu, carboxylic

amino-1-cyclohexane acid, Aib, carboxylic 2-aminotetraline, 4-bromophenylalanine, tert-Leucine, 4-chlorophenylalanine, β -cyclohexylalanine, 3,4-dichlorophenylalanine, 4-fluorophenylalanine, 5 homoleucine, β -homoleucine, homophenylalanine, 4-methylphenylalanine, 1-naphthylalanine, 2-naphthylalanine, 4-nitrophenylalanine, 3-nitrotyrosine, norvaline, phenylglycine, 3-pyridylalanine, [2-thienyl]alanine.

10

7. Linear peptide according to any one of claims 1 to 6, having the following sequences :

RGGRLSYSRRRFSVSVGR,
 RGVSVSFRRRSYSLRGGR,
 15 EGGELSYSEEEFSVSVGE,
 RGGRLAYRLLRFAIRVGR,
 OGGOXXBOXXOBXXXOXG,
 RAARLG YRXXRFGZRVGR,
 YRRRFSVSVR,
 20 RRLSYSRRRF,
 RRLSYSRRRFSVSVR,
 RGGRLSYSRRRFSTSTGR,

in which B represents Naphthylalanine, O represents Ornithine, X represents Norleucine and Z represents Norvaline.

25

8. Linear peptide according to any one of claims 1 to 6, having the following sequences :

KWSFRVSYRGISYRRSR,
 RWSFRVSYRGISYRRSR,
 RSRRYSIGRYSVRFSWK,
 OBXBOXXBOGXOBXXOX,
 5 KWAFRVAYRGIRYLLRL,
 KYAWRVAHRGIRWLLRX


in which B represents Napthylalanine, O represents Ornithine, X represents Norleucine and Z represents Norvaline.

10

9. Use of an antibiotic peptide or an analogue thereof, devoid of a disulphide bond, to vector active substances in an organism.

15 10. Use of a peptide according to any one of claims 1 to 8 to vector active substances in an organism.

11. Compound with the following formula (IV) :



20

in which :

- A represents a linear peptide derived from an antibiotic peptide or from an analogue thereof,

- Z represents an active substance

- Y represents a signal agent

25

- n is 0 or more, advantageously 0 or 1,


- m is 1 or more, preferably up to 10, advantageously up to 5.

12. Compound of formula (IV) in which A is defined as in any one of claims 1 to 8.
13. Compound according to one of claims 11 or 12, characterised in that the coupling between the linear peptide (A) and group (Z) or groups (Z) and (Y) is made by one or more covalent, hydrophobic or ionic bonds.
14. Compound according to any one of claims 11 to 13, characterised in that at least one of the active substances (Z) is attached by a covalent bond either to the N-terminal or C-terminal ends or to the primary amino groups, carried by the side chains of the lysines, of linear peptide (A).
15. Compound according to any one of claims 11 to 14, characterised in that at least one signal agent (Y), if present, is attached by a covalent bond to the N-terminal end of linear peptide (A).
16. Pharmaceutical composition, characterised in that as active ingredient it comprises at least one compound of formula (IV) according to any one of claims 11 to 15.
17. Diagnostic agent made up of at least one compound of formula (IV) according to any one of claims 11 to 15.

The invention concerns peptides derived from antibiotic peptides or analogues thereof, characterised in that they are devoid of sulphide bond. The invention also concerns the use of these linear peptides for vectoring chemical substances and chemical compounds formed by said peptides coupled with at least an active substance. The invention further concerns the preparation of said peptides and compositions containing them.

Figure 1


Texas Red



Hoechst


Peptide:SM1738

line :A172



Peptide:SM1738


line :HT29




2/5

Figure 2

Texas Red



Hoechst




Peptide: SM1738
line : HuVeC

000090 16550460

3/5

Figure 3


Texas Red



Hoechst

Peptide SM2307

line :A172



Peptide SM2307

line :HT29



006090" 16556460


Figure 4

Texas Red



Hoechst


Peptide SM2307
line :HuVeC



006090" T2990400

Figure 5

SM1738-dox
10 μ M, 60 min, MCF7



Express mail No:

Date of Deposit:

Attorney Docket No. 19904-009
(BREESE-9)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTORS:	Calas <i>et al.</i>
ASSIGNEE:	Synt:em
UNITED STATES NATIONAL PHASE OF PCT INTERNATIONAL APPLICATION NO:	PCT/FR98/01757
INTERNATIONAL FILING DATE:	August 6, 1997
FOR:	LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, PREPARATION AND USE FOR VECTORING ACTIVE SUBSTANCES

Box PCT

Assistant Commissioner for Patents
Washington, D.C. 20231

FRANCE

**DECLARATION AND POWER OF ATTORNEY FOR PATENT
APPLICATION
[DÉCLARATION ET POUVOIRS POUR DEMANDE
DE BREVET]**

As a below named inventor, I hereby declare that:

[En tant que l'inventeur nommé ci-après, je déclare par le présent acte que:]

My residence, post office address and citizenship are as stated next to my name.

[Mon domicile, mon adresse postale et ma nationalité sont ceux figurant ci-dessous à côté de mon nom.]

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled

**LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, PREPARATION AND
USE FOR VECTORING ACTIVE SUBSTANCES**

Je crois être u l'un des premiers coinventeurs originaux de l'objet revendiqué, pour lequel une demande de brevet a été déposée concernant l'invention intitulée

**PEPTIDES LINEAIRES DERIVES DE PEPTIDES ANTIBIOTIQUES, LEUR
PREPARATION AND LEUR UTILISATION POUR VECTORISER DES SUBSTANCES
ACTIVES**

the specification of which was filed on August 6, 1997 as PCT International Application
Number PCT/FR98/01757



INVENTORS: Calas et al.
UNITED STATES
NATIONAL PHASE OF PCT INTERNATIONAL
APPLICATION NO: PCT/FR98/01757

[et dont la description a été déposée le 6 août, 1997 sous le numéro de demande international PCT PCT/FR98/01757]

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

[Je déclare par le présent acte avoir passé en revue et compris le contenu de la description ci-dessus, revendications comprises, telles que modifiées par toute modification dont il aura été fait référence ci-dessus.]

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

[Je reconnais devoir divulguer toute information pertinente à la brevetabilité, comme défini dans le Titre 37, § 1.56 du Code fédéral des réglementations.]

I hereby claim foreign priority under Title 35, United States Code, § 119(a)-(d) of any foreign applications for patent or inventor's certificate listed below.

[Je revendique par le présent acte avoir la priorité étrangère, en vertu du Titre 35, § 119(a)-(d) du Code des Etats-Unis, sur toute demande étrangère de brevet ou certificat d'inventeur.]

Prior foreign application

Priority Claimed ☒

[Demande de brevet antérieure]

Droit de priorité revendiqué

97/10297

France

August 12, 1997

(Number)

(Country)

12 août 1997

(Numéro)

(Pays)

(Day/Month/Year Filed)

(Jour/Mois/Année de dépôt)

INVENTORS: Calas *et al.*
UNITED STATES
NATIONAL PHASE OF PCT INTERNATIONAL
APPLICATION NO: PCT/FR98/01757

I hereby claim the benefit under Tide 35, United States Code, §120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Tide 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Tide 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

[Je revendique par le présent acte tout bénéfice, en vertu du Titre 35, § 120 du Code des Etats-Unis, de toute demande de brevet effectuée aux Etats-Unis, ou en vertu du Titre 35, § 365(c) du même Code, de toute demande internationale PCT désignant les Etats-Unis et figurant ci-dessous et, dans la mesure où l'objet de chacune des revendications de cette demande de brevet n'est pas divulgué dans la demande antérieure américaine ou internationale PCT, en vertu des dispositions du premier paragraphe du Titre 35, § 112 du Code des Etats-Unis, je reconnais devoir divulguer toute information pertinente à la brevetabilité, comme défini dans le Titre 37, § 1.56 du Code fédéral des réglementations, dont j'ai pu disposer entre la date dépôt de la demande antérieure et la date de dépôt de la demande nationale ou internationale PCT de la présente demande:]

PCT/FR98/01757	<u>August 6, 1998</u>	<u>National stage</u>
	<u>6 aout 1998</u>	(Status) (patented, pending, abandoned)
(Application No.)	(Filing Date)	(Statut) (breveté, en cours d'examen,
(N° de demande)	(Date de dépôt)	abandonné)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Tide 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTORS: Calas et al.
UNITED STATES
NATIONAL PHASE OF PCT INTERNATIONAL
APPLICATION NO: PCT/FR98/01757

[Je déclare par le présent acte que toute déclaration ci-incluse est, à ma connaissance, véridique et que toute déclaration formulée à partir de renseignements ou de suppositions est tenue pour véridique; et de plus, que toutes ces déclarations ont été formulées en sachant que toute fausse déclaration volontaire ou son équivalent est passible d'une amende ou d'une incarcération, ou des deux, en vertu de la Section 1001 du Titre 18 du Code des Etats-Unis, et que de telles déclarations volontairement fausses risquent de compromettre la validité de la demande de brevet ou du brevet délivré à partir de celle-ci.]

POWER OF ATTORNEY [POUVOIRS]

As a named inventor, I hereby appoint the following attorneys and agents, all at MINTZ LEVIN, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

[En tant que l'inventeur cité, je désigne par la présente les avocats et agents, de MINTZ LEVIN, suivants pour qu'ils poursuivent la procédure de cette demande de brevet et traitent toute affaire s'y rapportant avec l'Office des brevets et des marques.]

Attorney or Agent	Registration No.	Attorney or Agent	Registration No.
David B. Bernstein	<u>32,112</u>	Leslie Meyer-Leon	<u>37,381</u>
David F. Crosby	<u>36,400</u>	A. Jason Mirabito	<u>28,161</u>
James G. Cullem	<u>43,569</u>	Michel Morency	Limited Recognition
Brett N. Dorny	<u>35,860</u>	John T. Prince	<u>43,091</u>
Ivor R. Elrifi	<u>39,529</u>	Brian Rosenbloom	<u>41,276</u>
John A. Harre	<u>37,345</u>	Carol H. Peters	<u>45,020</u>
Shane Hunter	<u>41,858</u>	Thomas M. Sullivan	<u>39,392</u>
David E. Johnson	<u>41,874</u>	Howard J. Susser	<u>33,556</u>
Robert Klauszinski	<u>42,742</u>	Shelby J. Walker	<u>45,192</u>
Kristin E. Konzak	<u>44,848</u>	Martin M. Zoltick	<u>35,745</u>
Cynthia Kozakiewicz	<u>42,764</u>	Marianne Downing	<u>42,870</u>
William A. Marino	<u>44,219</u>	Christina Karnakis	<u>P-45,899</u>
Barry J. Marenberg	<u>40,715</u>	Heidi A. Erlacher	<u>P-45,409</u>
Michael Renaud	<u>44,299</u>		

26

INVENTORS: Calas et al.
UNITED STATES
NATIONAL PHASE OF PCT INTERNATIONAL
APPLICATION NO: PCT/FR98/01757

Send Correspondence to:


[Adresser toute correspondance à]:

Ivor R. Elrifi
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, MA 02111

Direct Telephone Calls to


[Adresser tout appel téléphonique à]:

Ivor R. Elrifi
617 348-1747

00000000-1658160
Inventor's Signature 
Full Name of Inventor: Bernard CALAS
Citizenship: 1-00 France
Residence: 360, avenue du Père Prévost, F-34090 Montpellier, FRANCE
Post Office Address: 360, avenue du Père Prévost, F-34090 Montpellier, FRANCE


Date 29-03-2000

FRX

Inventor's Signature 
Full Name of Inventor: Gérard GRASSY
Citizenship: 2-00 France
Residence: 32 ~~32~~, rue du Pradas, F-34470 Pérols, FRANCE
Post Office Address: 32 ~~32~~, rue du Pradas, F-34470 Pérols, FRANCE

Date 11-04-2000

FRX

Inventor's Signature 
Full Name of Inventor: Alain CHAVANIEU
Citizenship: 3-00 France
Residence: 680, ch. des basquets, F-34820 Assas, FRANCE
Post Office Address: 680, ch. des basquets, F-34820 Assas, FRANCE

Date 1 04 2000

FRX

UNITED STATES
NATIONAL PHASE OF
PCT INTERNATIONAL
APPLICATION NO.:

Inventor's Signature

Michel KACZOREK

France

145, allée Charles Babbage, F-30900 Nîmes, FRANCE *FRX*

145, allée Charles Babbage, F-30900 Nîmes, FRANCE

Date _____

TRADOCS:1295943.1(RRYF01!.DOC)
02/24/00 6:11 PM

6